))
Resistance Mechanisms in EGFR+ mNSCLC
Manage episode 439565872 series 3599769
Content provided by Ontada Learn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ontada Learn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Welcome to episode two of three, where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). Explore the unmet needs in first-line therapy, the variety of resistance mechanisms, and the evolving landscape of treatment strategies.
13 episodes
Share
